August 22, 2022
Life Sciences
  • The Food and Drug Administration (FDA) approved Novavax’s COVID-19 vaccine for emergency use in adolescents, paving the way to expand eligibility for the fourth shot available in the U.S. The two-dose regimen utilizes protein-based technology previously leveraged in vaccines to combat other viruses, rather than the mRNA technology used in Pfizer and Moderna’s versions. The vaccine will be available to people aged 12 through 17, pending approval from the Centers for Disease Control and Prevention (CDC).  (Articles here, here, here, and here)